MDex vs BMDex for Untreated Systemic Light-chain (AL) Amyloidosis
AL Amyloidosis
Enrolment: 110 · Results not recorded
Loading the evidence…
Drug · INHIBITOR of the 26S proteasome; binds the chymotrypsin-like (beta5/MB1, P28074) subunit.
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
AL Amyloidosis
Enrolment: 110 · Results not recorded
Multiple Myeloma
Enrolment: 525 · Results not recorded
Multiple Myeloma · Renal Insuficiency
Enrolment: 72 · Results not recorded
Follicular Lymphoma
Enrolment: 87 · Results not recorded
Waldenstrom's Macroglobulinemia
Enrolment: 38 · Results not recorded
Lymphoma, Follicular
Enrolment: 14 · Results not recorded
Multiple Myeloma · Renal Impairment
Enrolment: 51 · Results not recorded
Smoldering Multiple Myeloma
Enrolment: 17 · Results not recorded
Solitary Plasmacytoma
Enrolment: 220 · Results not recorded
Mantle Cell Lymphoma
Enrolment: 30 · Results not recorded
Multiple Myeloma and Plasma Cell Neoplasm
Enrolment: 46 · Results not recorded
Refractory Multiple Myeloma
Enrolment: 64 · Results not recorded
Leukemia · Lymphoma
Enrolment: 18 · Results not recorded
Leukemia · Lymphoma · Multiple Myeloma
Enrolment: 18 · Results not recorded
Multiple Myeloma
Enrolment: 16 · Results not recorded
3 studies reported at therapy level; 3 evidence entries itemised.
Model: Acetaminophen-induced drug-induced liver injury, with additional carbon tetrachloride and thioacetamide hepatotoxicity models
Bortezomib alleviated acetaminophen, carbon tetrachloride and thioacetamide hepatotoxicity and reduced hepatic CYP2E1 expression and activity, whereas MG132 aggravated acetaminophen-induced injury.
Extraction: extract · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.
Model: Radiation-induced urinary bladder dysfunction in an established mouse bladder model, with single graded radiation doses in five dose groups; early dysfunction occurs in two phases during the first month after irradiation (phase I days 0 to 15, phase II days 16 to 30)
Daily bortezomib between days 0 and 15 significantly decreased the number of responders during phase I of radiation-induced bladder dysfunction. Daily bortezomib between days 16 and 30 had no significant effect. The authors conclude that the two waves of acute radiation-induced bladder dysfunction…
Extraction: extract · Supplied extraction confidence: 0.55. Machine-extracted fields require source verification.
Model: Mechanical brain lesion by controlled cortical impact
Proteasomal glucocorticoid receptor degradation was established in brain endothelial cells after controlled cortical impact. Combining bortezomib with dexamethasone restored occludin levels, improved blood-brain barrier integrity, reduced oedema formation and limited neuronal damage, offering a mec…
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.